NEW YORK — The US Food and Drug Administration this week granted separate Emergency Use Authorizations (EUAs) for SARS-CoV-2 tests developed by 3B Blackbio Biotech India, Bioperfectus Technologies, Omnipathology Solutions Medical, Biohit Healthcare, and Ohio State University.